title: More clearly defining the risks of erythrocyte transfusion in the NICU.
abstract: OBJECTIVE
  Red blood cell (RBC) transfusions convey benefits but they also carry risks. Among NICU patients, some transfusion risks are well defined and their occurrence odds can be estimated and weighed against benefits. However other risks are poorly defined and it is not currently possible to estimate their occurrence adds or weigh these against benefits.
  
  
  METHODS
  We reviewed publications in the past 15 years, listed in PubMed, dealing with risks and benefits of RBC transfusions to newborn infants.
  
  
  RESULTS
  Risks of RBC transfusion to adult patients decreased significantly with the advent of nucleic acid testing for viral pathogens. However, new or previously unknown risks of transfusions have been suggested for neonatal recipients. These include developmental delay, intraventricular hemorrhage, and necrotizing enterocolitis. These potential transfusion risks are all currently in the form of statistical associations, and cause-and-effect relationships have not been proven. Mean of reducing transfusions, tested during the past 15 years, include adopting transfusions guidelines, erythropoietic stimulating agents, delayed cord clamping, cord stripping, drawing all NICU admission blood tests from the placenta, and limiting phlebotomy losses for blood testing.
  
  
  CONCLUSIONS
  We advocate always attempt to weigh benefits and risks when ordering a transfusion for a neonatal patient. Certainly some such are life-saving or otherwise clearly beneficial. Perhaps others carry risks unbalanced by meager benefit. Efforts to improve NICU transfusion practice have been proposed and appear to be working to diminish costs and improve outcomes.
authors.affiliation: Women and Newborns Program, Intermountain Healthcare, McKay-Dee Hospital Center, Harrison Blvd, Ogden, UT 84403, USA. Robert.christensen@imail.org
authors.forename: Robert D
authors.initials: RD
authors.lastname: Christensen
authors.forename: Antonio
authors.initials: A
authors.lastname: Del Vecchio
authors.forename: Sarah J
authors.initials: SJ
authors.lastname: Ilstrup
mesh_terms: D000328:Adult; D000740:Anemia / Q000517:prevention & control / Q000628:therapy; D001804:Blood Transfusion, Autologous; D002543:Cerebral Hemorrhage / Q000209:etiology; D002658:Developmental Disabilities / Q000209:etiology; D020345:Enterocolitis, Necrotizing / Q000209:etiology; D017707:Erythrocyte Transfusion / Q000009:adverse effects* / Q000706:statistics & numerical data; D004921:Erythropoietin / Q000009:adverse effects / Q000627:therapeutic use; D005312:Fetal Blood; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000209:etiology / Q000517:prevention & control / Q000628:therapy; D019102:Infant, Very Low Birth Weight; D007363:Intensive Care Units, Neonatal; D018570:Risk Assessment; D012307:Risk Factors; D014470:Umbilical Cord
chemical_list: D004921:Erythropoietin